Piper Sandler analyst Joseph Catanzaro downgraded Mirati Therapeutics (MTRX) to Neutral from Overweight with a $58 price target after Bristol Myers Squibb (BMY) said it will acquire Mirati for $58 per share plus a contingent value right of $12 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Biotech Alert: Searches spiking for these stocks today
- Oracle upgraded, Spotify downgraded: Wall Street’s top analyst calls
- Bristol Myers acquisition to bolster oncology portfolio, says JPMorgan
- Bristol Myers multiple paid for Mirati ‘looks reasonable,’ says BofA
- Mirati Therapeutics downgraded to Neutral from Buy at B. Riley